Skip to main content


Hepatology International

Hepatology International OnlineFirst articles

18.01.2021 | Original Article

Prediction of liver-related events in patients with compensated HBV-induced cirrhosis receiving antiviral therapy

Approximately 250 million people are hepatitis B surface antigen (HBsAg) positive globally [ 1 , 2 ]. Chronic hepatitis B virus (HBV) infection is one of the most common causes of liver cirrhosis. Patients with cirrhosis are at higher risk of …

16.01.2021 | Editorial

Sequential combination therapies for HBeAg-positive chronic hepatitis B: the search continues

10.01.2021 | Original Article

Dipeptidyl peptidase-4 inhibitors may accelerate cirrhosis decompensation in patients with diabetes and liver cirrhosis: a nationwide population-based cohort study in Taiwan

Management of type 2 diabetes mellitus (T2DM) in patients with liver cirrhosis is difficult. Many drugs are metabolized by the liver; thus, patients with advanced liver disease experience decreased medication excretion and increased toxicity [ 1 ].

09.01.2021 | Original Article

Phase 2 trial comparing sorafenib, pravastatin, their combination or supportive care in HCC with Child–Pugh B cirrhosis

Hepatocellular carcinoma (HCC) is the fourth cause of cancer death worldwide [ 1 ]. The mortality is rising in Western Countries [ 2 ]. Most HCC arise in patients with cirrhosis. In these patients, HCC and cirrhosis are both at risk of …

09.01.2021 | COVID-19 | Letter to the Editor Zur Zeit gratis

Reductions in liver cirrhosis hospitalizations during the COVID-19 pandemic

The coronavirus disease-2019 (COVID-19) pandemic has changed the world and placed a huge strain on health care systems worldwide. Many hospitals have intentionally reduced non-emergency procedures and hospitalizations for some reasons. Some …

Aktuelle Ausgaben

Über diese Zeitschrift

Hepatology International is a peer-reviewed journal featuring articles written by clinicians, clinical researchers and basic scientists is dedicated to research and patient care issues in hepatology. This journal focuses mainly on new and emerging diagnostic and treatment options, protocols and molecular and cellular basis of disease pathogenesis, new technologies, in liver and biliary sciences.

Hepatology International publishes original research articles related to clinical care and basic research; review articles; consensus guidelines for diagnosis and treatment; invited editorials, and controversies in contemporary issues. The journal does not publish case reports..

Hepatology International requests that all authors comply to Springer’s ethical policies. These ethical statements should be clearly indicated on all articles for all 3 ethics statements and for all authors mentioned by name. These statements should be placed at the end of each article just before the Reference section.

To visit our ethics statements please visit the following links:

Conflict of Interest and Ethical Standards:

Informed Consent:

Statement of Human and Animal Rights:

Hepatology International is the official journal of the Asian Pacific Association for the Study of the Liver (APASL).

Now indexed by ISI

Weitere Informationen

Neu im Fachgebiet Innere Medizin

Mail Icon II Newsletter

Bestellen Sie unseren kostenlosen Newsletter Update Innere Medizin und bleiben Sie gut informiert – ganz bequem per eMail.

© Springer Medizin